Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Liabilities for 3 consecutive years, with $564.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 62.83% to $564.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $564.2 million through Dec 2025, up 62.83% year-over-year, with the annual reading at $564.2 million for FY2025, 62.83% up from the prior year.
  • Total Liabilities for Q4 2025 was $564.2 million at Kura Oncology, up from $406.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $564.2 million in Q4 2025, with the low at $30.8 million in Q1 2023.
  • Average Total Liabilities over 3 years is $199.0 million, with a median of $53.4 million recorded in 2023.
  • The sharpest move saw Total Liabilities increased 25.62% in 2024, then skyrocketed 676.99% in 2025.
  • Over 3 years, Total Liabilities stood at $51.7 million in 2023, then skyrocketed by 570.74% to $346.5 million in 2024, then surged by 62.83% to $564.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $564.2 million, $406.8 million, and $376.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.